<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04913077</url>
  </required_header>
  <id_info>
    <org_study_id>PV7129</org_study_id>
    <nct_id>NCT04913077</nct_id>
  </id_info>
  <brief_title>Submucosal Tumor Removal by Endoscopic Excision Therapy</brief_title>
  <acronym>STREET</acronym>
  <official_title>Prospective One-armed Observational Study of Full-thickness Resection of Small Hypoechoic Submucosal Gastric Tumors (≤2 cm)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ovesco Endoscopy AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Smaller submucosal tumors (SMT) in the stomach are usually seen as an incidental finding&#xD;
      during a gastroscopy, although current diagnostics usually do not clearly indicate what type&#xD;
      of tumor it is. In summary, there is no good evidence for dealing with SMT. In this study, an&#xD;
      endoscopic full-thickness resection, primarily with the FTRD device, is to be offered to all&#xD;
      patients with gastric SMT without a confirmed histology seen in a certain period of time .&#xD;
      Patients who do not want to take advantage of this are included in a systematic follow-up&#xD;
      program.&#xD;
&#xD;
      The investigators hope to learn about the rate of so-called GIST tumors and other&#xD;
      histologies, as well as the rate of change in the follow-up group.&#xD;
&#xD;
      Also, study contents will be accuracy of endosonographic imaging and puncture in comparison&#xD;
      with resection histology, technical feasibility and histological completeness of the FTRD-&#xD;
      based endoscopic (full-wall) resection option, complications of such a resection (secondary&#xD;
      bleeding and dehiscences), and patient preferences with standardized information.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Smaller submucous tumors in the stomach are usually seen as a random finding in gastroscopies&#xD;
      and present a diagnostic dilemma to the doctor and patient:&#xD;
&#xD;
      type specification is usually unclear whether it is an absolutely benign (without&#xD;
      degeneration potential) or a malignant or prone tumor (usually gastrointestinal stromal&#xD;
      tumor, GIST). However, this is crucial for further management.&#xD;
&#xD;
      In endosonographic imaging there are only approximate values in the differential diagnosis&#xD;
      between GIST and non-GIST, the endoscopic biopsy is too superficial, and the hit rate of&#xD;
      endosonographic pin puncture is limited, and in most studies is less than 70% Therefore, one&#xD;
      can only make assumptions and create a risk profile from imaging and tumor size (limit size 3&#xD;
      cm, partly also 2 cm). Both follow-up recommendations (rather no GIST) and laparoscopic&#xD;
      surgical removal (proven or probable/possible GIST) are not rarely without clear preference,&#xD;
      especially for smaller tumors.&#xD;
&#xD;
      For these indications, a simple endoscopic removal option comparable to the polypectomy in&#xD;
      the colon (where no histological type diagnosis is made before) does not exist.&#xD;
&#xD;
      Previous studies are usually subject to bias in several directions:&#xD;
&#xD;
        1. The frequency of GIST tumors among submucous tumors/lesions (SMT) in the stomach is&#xD;
           unclear. Gastroenterological series always contain smaller GIST tumors, but are reported&#xD;
           almost exclusively from clinics. The rate of these tumors in the overall collective of&#xD;
           patients seen in the field of (mostly established) gastroenterologists is thus&#xD;
           completely unclear. Surgical or oncological series have usually included more aggressive&#xD;
           tumors consisting mainly or exclusively of GIST tumors, therefore do not allow&#xD;
           epidemiological conclusions.&#xD;
&#xD;
        2. If no surgery is performed (and thus a definitive histology is forced), only information&#xD;
           from follow-up examinations remains. Previous follow-up studies show the dilemma of&#xD;
           insufficient differential diagnosis of lesions by endosonography and (endosonographic or&#xD;
           other) biopsy, which usually have insufficient accuracy. In addition, the follow-up time&#xD;
           in the studies hardly extends beyond 2 years. The &quot;gastroenterological gut instinct&quot;&#xD;
           that these small lesions are not dangerous may be true, but is not proven.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2020</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Submucosal gastric Tumors up to 2 centimeters of size</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of GIST tumors</measure>
    <time_frame>through study completion, approximately 2 years</time_frame>
    <description>Rate of GIST tumors in a preferably unselected patient cohort of small submucous gastric tumors in which histology is not known</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success</measure>
    <time_frame>through study completion, approximately 2 years</time_frame>
    <description>Technical success rate (R0/R1 resection) of the chosen resection technique</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rate</measure>
    <time_frame>through study completion, approximately 2 years</time_frame>
    <description>Complication rate of the chosen resection technique</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>influencing factors on the GIST rate: tumor size</measure>
    <time_frame>through study completion, approximately 2 years</time_frame>
    <description>Influence of tumor size on the GIST rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influencing factors on the GIST rate: position of tumor</measure>
    <time_frame>through study completion, approximately 2 years</time_frame>
    <description>Influence of tumor position in the stomach</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influencing factors on the GIST rate: endoscopic ultrasound image</measure>
    <time_frame>through study completion, approximately 2 years</time_frame>
    <description>endoscopic ultrasound image with pattern and position in the wall</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influencing factors on the GIST rate: patient's age</measure>
    <time_frame>through study completion, approximately 2 years</time_frame>
    <description>Age of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influencing factors on the GIST rate: patient's gender</measure>
    <time_frame>through study completion, approximately 2 years</time_frame>
    <description>gender of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influencing factors on the GIST rate: anamnesis</measure>
    <time_frame>through study completion, approximately 2 years</time_frame>
    <description>anamnesis including initial diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's preferred approach</measure>
    <time_frame>through study completion, approximately 2 years</time_frame>
    <description>Patient preferences for removal (consent rate for the study) versus follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>data for cost-benefit calculation</measure>
    <time_frame>through study completion, approximately 2 years</time_frame>
    <description>Establishment of a date base for a cost-benefit calculation comparing follow-up vs. removal</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Submucosal Tumor of Stomach</condition>
  <arm_group>
    <arm_group_label>Removal of submucosal gastric tumor preferably by Full Thickness Resection Device (FTRD)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FTRD (Ovesco company) in tumors up to 10 mm and predominantly intraluminal growth directly by sucking into the cap, at 10-20 mm and/or intramural/extramural growth by prior circumcision and lateral preparation, so that the lesions can be better pulled into the cap. The procedure depends on the endosonographic extent of the findings. The lesions are pulled into the cap with grippers and other instruments and, if necessary, with a snare and then resected with FTRD</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>removal of submucosal gastric tumor preferably by Full Thickness Resection Device (FTRD)</intervention_name>
    <description>FTRD (Ovesco company) in tumors up to 10 mm and predominantly intraluminal growth directly by sucking into the cap, at 10-20 mm and/or intramural/extramural growth by prior circumcision and lateral preparation, so that the lesions can be better pulled into the cap. The procedure depends on the endosonographic extent of the findings. The lesions are pulled into the cap with grippers and other instruments and, if necessary, with a snare and then resected with FTRD</description>
    <arm_group_label>Removal of submucosal gastric tumor preferably by Full Thickness Resection Device (FTRD)</arm_group_label>
    <other_name>Endoscopic submucosal dissection (ESD)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with endoscopically diagnosed and endosonographically confirmed submucosal&#xD;
             tumors of 0.5 to 2 cm in the stomach without definitive histology / cytology&#xD;
&#xD;
          -  Initial diagnosis less than 2 years ago&#xD;
&#xD;
          -  No contraindication to endoscopic resection&#xD;
&#xD;
          -  Patient's informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumor size &gt; 2 cm&#xD;
&#xD;
          -  Tumors with proven / suspected malignancy for which oncologically no endoscopic&#xD;
             resection should be performed, i.e. for which oncological or surgical therapy is&#xD;
             planned&#xD;
&#xD;
          -  SMT known &gt; 2 Years&#xD;
&#xD;
          -  Patients with severe general illnesses (limited operability) or malignancies&#xD;
&#xD;
          -  Clotting disorders&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Rösch, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Rösch, Prof. Dr.</last_name>
    <phone>+49 40 7410</phone>
    <phone_ext>50098</phone_ext>
    <email>t.roesch@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guido Schachschal, PD Dr.</last_name>
    <phone>+49 40 7410</phone>
    <phone_ext>50097</phone_ext>
    <email>g.schachschal@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Rösch, Prof. Dr.</last_name>
      <phone>+49 40 7410</phone>
      <phone_ext>50098</phone_ext>
      <email>t.roesch@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Guido Schachschal, PD Dr.</last_name>
      <phone>+49 49 7410</phone>
      <phone_ext>50097</phone_ext>
      <email>g.schachschal@uke.de</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Rösch, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guido Schachschal, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lennika Calavrezos, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katharina Zimmermann-Fraedrich, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philip Dautel, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Cai MY, Martin Carreras-Presas F, Zhou PH. Endoscopic full-thickness resection for gastrointestinal submucosal tumors. Dig Endosc. 2018 Apr;30 Suppl 1:17-24. doi: 10.1111/den.13003. Review.</citation>
    <PMID>29658639</PMID>
  </reference>
  <reference>
    <citation>Akahoshi K, Oya M, Koga T, Shiratsuchi Y. Current clinical management of gastrointestinal stromal tumor. World J Gastroenterol. 2018 Jul 14;24(26):2806-2817. doi: 10.3748/wjg.v24.i26.2806. Review.</citation>
    <PMID>30018476</PMID>
  </reference>
  <reference>
    <citation>Cazacu IM, Luzuriaga Chavez AA, Nogueras Gonzalez GM, Saftoiu A, Bhutani MS. Malignant Transformation of Ectopic Pancreas. Dig Dis Sci. 2019 Mar;64(3):655-668. doi: 10.1007/s10620-018-5366-z. Epub 2018 Nov 10. Review.</citation>
    <PMID>30415408</PMID>
  </reference>
  <reference>
    <citation>Standards of Practice Committee, Faulx AL, Kothari S, Acosta RD, Agrawal D, Bruining DH, Chandrasekhara V, Eloubeidi MA, Fanelli RD, Gurudu SR, Khashab MA, Lightdale JR, Muthusamy VR, Shaukat A, Qumseya BJ, Wang A, Wani SB, Yang J, DeWitt JM. The role of endoscopy in subepithelial lesions of the GI tract. Gastrointest Endosc. 2017 Jun;85(6):1117-1132. doi: 10.1016/j.gie.2017.02.022. Epub 2017 Apr 3.</citation>
    <PMID>28385194</PMID>
  </reference>
  <reference>
    <citation>Kida M, Kawaguchi Y, Miyata E, Hasegawa R, Kaneko T, Yamauchi H, Koizumi S, Okuwaki K, Miyazawa S, Iwai T, Kikuchi H, Watanabe M, Imaizumi H, Koizumi W. Endoscopic ultrasonography diagnosis of subepithelial lesions. Dig Endosc. 2017 May;29(4):431-443. doi: 10.1111/den.12854. Epub 2017 Apr 6. Review.</citation>
    <PMID>28258621</PMID>
  </reference>
  <reference>
    <citation>Kim SY, Kim KO. Management of gastric subepithelial tumors: The role of endoscopy. World J Gastrointest Endosc. 2016 Jun 10;8(11):418-24. doi: 10.4253/wjge.v8.i11.418. Review.</citation>
    <PMID>27298713</PMID>
  </reference>
  <reference>
    <citation>Kim SY, Kim KO. Endoscopic Treatment of Subepithelial Tumors. Clin Endosc. 2018 Jan;51(1):19-27. doi: 10.5946/ce.2018.020. Epub 2018 Jan 31. Review.</citation>
    <PMID>29397653</PMID>
  </reference>
  <reference>
    <citation>Lim TW, Choi CW, Kang DH, Kim HW, Park SB, Kim SJ. Endoscopic ultrasound without tissue acquisition has poor accuracy for diagnosing gastric subepithelial tumors. Medicine (Baltimore). 2016 Nov;95(44):e5246. doi: 10.1097/MD.0000000000005246.</citation>
    <PMID>27858880</PMID>
  </reference>
  <reference>
    <citation>Marcella C, Shi RH, Sarwar S. Clinical Overview of GIST and Its Latest Management by Endoscopic Resection in Upper GI: A Literature Review. Gastroenterol Res Pract. 2018 Oct 31;2018:6864256. doi: 10.1155/2018/6864256. eCollection 2018. Review.</citation>
    <PMID>30515204</PMID>
  </reference>
  <reference>
    <citation>Moon JS. Role of Endoscopic Ultrasonography in Guiding Treatment Plans for Upper Gastrointestinal Subepithelial Tumors. Clin Endosc. 2016 May;49(3):220-5. doi: 10.5946/ce.2016.047. Epub 2016 May 20. Review.</citation>
    <PMID>27209643</PMID>
  </reference>
  <reference>
    <citation>Bruno M, Carucci P, Repici A, Pellicano R, Mezzabotta L, Goss M, Magnolia MR, Saracco GM, Rizzetto M, De Angelis C. The natural history of gastrointestinal subepithelial tumors arising from muscularis propria: an endoscopic ultrasound survey. J Clin Gastroenterol. 2009 Oct;43(9):821-5. doi: 10.1097/MCG.0b013e31818f50b8.</citation>
    <PMID>19349904</PMID>
  </reference>
  <reference>
    <citation>Kim MY, Jung HY, Choi KD, Song HJ, Lee JH, Kim DH, Choi KS, Lee GH, Kim JH. Natural history of asymptomatic small gastric subepithelial tumors. J Clin Gastroenterol. 2011 Apr;45(4):330-6. doi: 10.1097/MCG.0b013e318206474e.</citation>
    <PMID>21278578</PMID>
  </reference>
  <reference>
    <citation>Kushnir VM, Keswani RN, Hollander TG, Kohlmeier C, Mullady DK, Azar RR, Murad FM, Komanduri S, Edmundowicz SA, Early DS. Compliance with surveillance recommendations for foregut subepithelial tumors is poor: results of a prospective multicenter study. Gastrointest Endosc. 2015;81(6):1378-84. doi: 10.1016/j.gie.2014.11.013. Epub 2015 Feb 7.</citation>
    <PMID>25660977</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 23, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2021</study_first_posted>
  <last_update_submitted>June 20, 2021</last_update_submitted>
  <last_update_submitted_qc>June 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Submucosal Tumor of Stomach</keyword>
  <keyword>GIST</keyword>
  <keyword>FTRD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

